NYSE · GSK
GSK financials
$49.35−0.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.93B | $39.37B | $38.61B | $35.48B | $33.39B | $31.32B | $44.76B | $39.26B | $40.79B | $34.42B |
| Gross profit | $31.80B | $28.02B | $27.70B | $23.92B | $22.35B | $21.13B | $29.03B | $26.21B | $26.82B | $22.95B |
| Gross margin | 72.4% | 71.2% | 71.8% | 67.4% | 66.9% | 67.4% | 64.9% | 66.8% | 65.7% | 66.7% |
| Operating income | $10.67B | $5.05B | $8.59B | $7.78B | $6.01B | $5.40B | $8.77B | $6.60B | $5.04B | $2.72B |
| Net income | $7.69B | $3.23B | $6.27B | $18.09B | $4.75B | $8.22B | $6.16B | $4.61B | $2.07B | $1.13B |
| Net margin | 17.5% | 8.2% | 16.2% | 51.0% | 14.2% | 26.2% | 13.8% | 11.8% | 5.1% | 3.3% |
| Diluted EPS | $1.87 | $0.78 | $1.53 | $4.43 | $1.17 | $2.06 | $1.23 | $0.93 | $0.42 | $0.23 |
| EBITDA | $10.67B | $5.05B | $8.59B | $7.78B | $6.01B | $5.40B | $8.77B | $6.60B | $5.04B | $2.72B |
| Operating cash flow | $10.41B | $8.22B | $8.62B | $8.96B | $10.75B | $12.25B | $10.64B | $10.73B | $9.35B | $8.02B |
| Free cash flow | $8.60B | $6.47B | $6.94B | $7.57B | $9.47B | $10.98B | $8.96B | $9.01B | $7.26B | $6.11B |
| Diluted shares | 4,117.0M | 4,142.0M | 4,111.0M | 4,084.0M | 4,052.0M | 3,981.0M | 5,016.0M | 4,971.0M | 4,941.0M | 4,909.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.57B | $4.86B | $3.74B | $4.50B | $5.90B | $8.60B |
| Short-term investments | $12.1M | $26.4M | $2.86B | $5.03B | $84.1M | $0.00 |
| Total debt | $31.07B | $28.98B | $22.94B | $25.39B | $33.35B | $37.12B |
| Total assets | $82.19B | $74.62B | $75.11B | $72.76B | $109.12B | $109.97B |
| Total liabilities | $60.73B | $58.19B | $58.83B | $60.55B | $79.68B | $81.52B |
| Shareholders' equity | $21.46B | $16.42B | $16.29B | $12.21B | $29.44B | $28.45B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology